Receptor-mediated transcytosis of cyclophilin B through the blood-brain barrier

International audienceCyclophilin B (CyPB) is a cyclosporin A (CsA)- binding protein mainly located in intracellular vesicles and secreted in biological fluids. In previous works, we demonstrated that CyPB interacts with T lymphocytes and enhances in vitro cellular incorporation and activity of CsA. In addition to its immunosuppressive activity, CsA is able to promote regeneration of damaged peripheral nerves. However, the crossing of the drug from plasma to neural tissue is restricted by the relative impermeability of the blood–brain barrier. To know whether CyPB might also participate in the delivery of CsA into the brain, we have analyzed the interactions of CyPB with brain capillary endothelial cells. First, we demonstrated that CyPB binds to two types of binding sites present at the surface of capillary endothelial cells from various species of tissues. The first type of binding sites (KD = 300 nM; number of sites = 3 x 106) is related to interactions with negatively charged compounds such as proteoglycans. The second type of binding sites, ~50,000 per cell, exhibits a higher affinity for CyPB (KD = 15 nM) and is involved in an endocytosis process, indicating it might correspond to a functional receptor. Finally, the use of an in vitro model of blood–brain barrier allowed us to demonstrate that CyPB is transcytosed by a receptor-mediated pathway (flux = 16.5 fmol/cm²/h). In these conditions, CyPB did not significantly modify the passage of CsA, indicating that it is unlikely to provide a pathway for CsA brain delivery

Fetal bovine serum impacts the observed N‐glycosylation defects in TMEM165 KO HEK cells

International audienc